Summary: Researchers present preliminary findings of Alzheimer’s disease onset and progression in Mexican Americans and other diverse, often overlooked populations.
Source: University of North Texas
A growing trove of data to help scientists understand the biology of Alzheimer’s disease among diverse populations within the context of sociocultural, behavioral and environmental factors is now available through the Institute for Translational Research at The University of North Texas Health Science Center at Fort Worth (HSC).
The research data is the result of the Health and Aging Brain among Latino Elders (HABLE) study launched in 2017 with $12 million in funding from the National Institutes of Health and headed by Sid O’Bryant, PhD, Executive Director of the Institute.
In 2020, the HABLE study received an additional $45 million from National Institute on Aging, part of the National Institutes of Health.
Dr. O’Bryant announced the availability of the research data in article published June 21 in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, a national journal published by the Alzheimer’s Association.
“The data from this study is a first-of-a-kind for the field,” Dr. O’Bryant said. “We will for the first time be able to examine the biology of Alzheimer’s among Mexican Americans as well as non-Hispanic whites all within the context of sociocultural, environmental and behavioral factors. Scientists from across the globe can use this data to address health disparities and define new diagnostic and treatment opportunities for underserved communities.”
The percentage of Hispanics 65 and above in the U.S. will triple by the year 2050 and, when compared to other racial or ethnic groups, are expected to experience the largest increase in Alzheimer’s disease related dementias by 2060, according to the paper. About 65 percent of U.S. Hispanics are of Mexican decent.
However, Mexican Americans are severely underrepresented in Alzheimer’s research, resulting too few comprehensive studies of the biomarkers of the disease among this population. Early findings suggest that beta amyloid protein — one of the biomarkers of Alzheimer’s — is less common among Mexican Americans yet Mexican Americans seem to have a younger onset of cognitive loss.
About 1,000 Mexican Americans and 1,000 non-Latino whites over 50 from North Texas have enrolled in the study that gives participants reoccurring and free comprehensive interviews, functional exams, clinical laboratory tests, a brain MRI and state-of-the-art PET Scans.
The PET Scans allow researchers to observe the differences over time in the development of the biomarkers between Mexican Americans and non-Latino whites.
In December, HSC announced an additional $7 million investment that to add 1,000 African Americans to the study. Among people 65 and older,?African Americans have the highest prevalence of Alzheimer’s disease, followed by Hispanics and non-Latino?whites, according to the U.S. Center for?Disease Control and Prevention.
The project is the only comprehensive, large-scale Alzheimer’s research study into the three largest ethnic groups in the U.S. – Non-Hispanic whites, Mexican Americans and African Americans.
About this Alzheimer’s disease research news
Source: University of North Texas
Contact: Alex Branch – University of North Texas
Image: The image is in the public domain
Original Research: Open access.
“The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics” by Sid O’Bryant et al. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Abstract
The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics
Introduction
Mexican Americans remain severely underrepresented in Alzheimer’s disease (AD) research. The Health & Aging Brain among Latino Elders (HABLE) study was created to fill important gaps in the existing literature.
Methods
Community-dwelling Mexican Americans and non-Hispanic White adults and elders (age 50 and above) were recruited. All participants underwent comprehensive assessments including an interview, functional exam, clinical labs, informant interview, neuropsychological testing, and 3T magnetic resonance imaging (MRI) of the brain. Amyloid and tau positron emission tomography (PET) scans were added at visit 2. Blood samples were stored in the Biorepository.
Results
Data was examined from n = 1705 participants. Significant group differences were found in medical, demographic, and sociocultural factors. Cerebral amyloid and neurodegeneration imaging markers were significantly different between Mexican Americans and non-Hispanic Whites.
Discussion
The current data provide strong support for continued investigations that examine the risk factors for and biomarkers of AD among diverse populations.
